HorizonStrategiesEurope · Trans-Caspian · Beyond

Healthcare and life sciences

Direct answer

Healthcare and life sciences require a product-specific regulatory and institutional route; regional health priorities are not market authorisations. What clinical, procurement and registration path applies to the specific offer? Distinguish public procurement, private-provider, distributor and donor pathways. Map registration, reimbursement, clinical evidence, installation, training and servicing before approaching institutions. The Unified Portal of Interactive Public Services describes a state-registration route for medical products and cites the applicable legal basis.

Editorial author
Horizon Strategies
Scope
Healthcare and life sciences
Key facts and evidence
Fact or procedureRecorded evidenceAuthority and sourceChecked
Uzbekistan · Uzbekistan health: registration, quality reform and system strategy require an exact product, responsible party and purchaser routeThe Unified Portal of Interactive Public Services describes a state-registration route for medical products and cites the applicable legal basis. General service information does not determine the classification, dossier, evidence, fee, duration or outcome for a specific product.Unified Portal of Interactive Public Services — medical-device registration serviceOriginal source2026-10-12
Azerbaijan · Azerbaijan health: mandatory-insurance, provider and assistive-technology signals require a defined purchaser and product routeThe European Observatory records the separation of regulator, purchaser and provider roles: the Ministry of Health retains policy responsibility, the State Agency on Mandatory Health Insurance manages mandatory-insurance revenues and TƏBİB is the main public-service provider. Institutional roles do not identify a tender, facility buyer, budget or product acceptance for a defined offer.Azerbaijan Ministry of Health — health and customs cooperation on medicines and medical devices, 19 June 2026Original source2026-10-12
Azerbaijan · Azerbaijan health: TƏBİB facility-modernisation activity creates an asset-specific medtech research routeTƏBİB’s 2025 results briefing describes 2026 work on biological-protection systems in 50 Baku medical institutions and plans for similar work across 132 medical institutions, alongside named hospital, polyclinic, emergency and modular-facility projects. The statement identifies a public-facility modernisation agenda; it does not establish a live procurement, technical specification, facility budget, selection decision or supplier route.TƏBİB — 2025 results briefing and 2026 public-facility modernisation programmeOriginal source2026-10-20
Georgia · Georgia health technology: a mixed-provider system creates defined product and purchaser routesGeostat’s current health series records 15.2 thousand hospital beds and 16.76 million outpatient visits for 2025. Aggregate capacity and use data describe the system; they do not identify a facility need, capital budget, buyer, clinical pathway, product acceptance or contract route for a defined offer.National Statistics Office of Georgia — healthcare indicators through 2025Original source2026-10-12
Armenia · Armenia health: insurance reform and digital-system evidence require a care-setting, purchasing and data-delivery caseWHO’s 2026 Armenia evaluation reports continuing health-system transformation across primary care, noncommunicable disease prevention, emergency preparedness and health-financing reform, while also identifying resource mobilisation, staffing and results-monitoring constraints. System reform is not a product approval, buyer mandate, reimbursement decision or procurement route.WHO Europe — contribution in Armenia 2020–2024: evaluation report, 1 October 2026Original source2026-10-12
Türkiye · Türkiye health technology: industrial scale and public procurement signals require a product-, registration- and buyer-specific routeTürkiye’s Ministry of Health reported at a May 2026 medical-device governance summit that local production represented more than 31% of public medical-device procurement and that the national product-tracking system covered approximately 5.3 million devices. Ministerial figures describe the policy and operating environment; they do not constitute registration, reimbursement, procurement eligibility, a distributor appointment or buyer demand for a particular product.Türkiye Ministry of Health — Medical Device Governance Summit, 12 May 2026Original source2026-10-12
Kazakhstan · Kazakhstan healthcare and medical devices: system need and procurement context require a product- and purchaser-specific gateThe Ministry of Health reported a 2026 procurement campaign covering more than 2,000 medicine and medical-device items under the guaranteed free medical-care and compulsory social-health-insurance frameworks. A campaign update describes a public purchasing context; it does not establish an open lot, a technical specification, product registration, supplier eligibility, price, award or customer route for a particular offer.Kazakhstan Ministry of Health — 2026 medicines and medical-devices procurement updateOriginal source2026-10-11
Kyrgyz Republic · Kyrgyz Republic health systems: strategy and project disclosures require a facility, product and procurement gateWHO’s Kyrgyzstan country material frames the 2024–2030 cooperation strategy around jointly identified health priorities; a country-cooperation strategy does not identify a facility need, buyer, procurement package, product registration, reimbursement route or permitted clinical use.WHO — Kyrgyzstan country and cooperation-strategy materialOriginal source2026-10-20
Tajikistan · Tajikistan health: visible public procurement supports facility, product and purchasing-route researchThe Ministry of Health and Social Protection is the accountable public-sector reference, while WHO/European Observatory material describes a largely public and centrally governed system with a small private sector. This does not identify a purchasing authority, facility need or commercial route for a named offer.Ministry of Health and Social Protection — official portalOriginal source2026-10-12
Turkmenistan · Turkmenistan health: strategy, medical-cluster and facility signals require an exact authority, product-registration and delivery routeTurkmenistan approved a 2026–2052 scientific-medical diplomacy strategy and a 2026–30 action plan. An approved strategy is a high-level policy instrument; it does not establish a procurement package, budget, product need, registration outcome, hospital access, clinical acceptance, purchaser authority or payment route for a defined supplier.Turkmenistan state information portal — 2026–2052 scientific-medical diplomacy strategy approvalOriginal source2026-10-13
Kyrgyz Republic · Kyrgyz Republic health: 2026 medicines and device rules create a defined registration-and-delivery routeCabinet of Ministers Resolution No. 670 of 6 October 2026 approved national lists of vital medicines and medical devices for 2026 to 2028. The lists are a current public reference for product and health-system research, but inclusion or exclusion does not establish registration, procurement, reimbursement, hospital demand, import permission, supplier eligibility or sale of a particular product.Cabinet of Ministers of the Kyrgyz Republic: Resolution No. 670, national vital medicines and medical-devices lists for 2026 to 2028Original source2026-10-20

Limits and what this does not prove: No medicine, device, diagnostic or digital-health conclusion can be made without the current national authority process and an eligible local route.

Decision question

What clinical, procurement and registration path applies to the specific offer?

Route to evidence

Distinguish public procurement, private-provider, distributor and donor pathways. Map registration, reimbursement, clinical evidence, installation, training and servicing before approaching institutions.

Country evidence

The Unified Portal of Interactive Public Services describes a state-registration route for medical products and cites the applicable legal basis. General service information does not determine the classification, dossier, evidence, fee, duration or outcome for a specific product.

The European Observatory records the separation of regulator, purchaser and provider roles: the Ministry of Health retains policy responsibility, the State Agency on Mandatory Health Insurance manages mandatory-insurance revenues and TƏBİB is the main public-service provider. Institutional roles do not identify a tender, facility buyer, budget or product acceptance for a defined offer.

TƏBİB’s 2025 results briefing describes 2026 work on biological-protection systems in 50 Baku medical institutions and plans for similar work across 132 medical institutions, alongside named hospital, polyclinic, emergency and modular-facility projects. The statement identifies a public-facility modernisation agenda; it does not establish a live procurement, technical specification, facility budget, selection decision or supplier route.

Geostat’s current health series records 15.2 thousand hospital beds and 16.76 million outpatient visits for 2025. Aggregate capacity and use data describe the system; they do not identify a facility need, capital budget, buyer, clinical pathway, product acceptance or contract route for a defined offer.

WHO’s 2026 Armenia evaluation reports continuing health-system transformation across primary care, noncommunicable disease prevention, emergency preparedness and health-financing reform, while also identifying resource mobilisation, staffing and results-monitoring constraints. System reform is not a product approval, buyer mandate, reimbursement decision or procurement route.

Türkiye’s Ministry of Health reported at a May 2026 medical-device governance summit that local production represented more than 31% of public medical-device procurement and that the national product-tracking system covered approximately 5.3 million devices. Ministerial figures describe the policy and operating environment; they do not constitute registration, reimbursement, procurement eligibility, a distributor appointment or buyer demand for a particular product.

The Ministry of Health reported a 2026 procurement campaign covering more than 2,000 medicine and medical-device items under the guaranteed free medical-care and compulsory social-health-insurance frameworks. A campaign update describes a public purchasing context; it does not establish an open lot, a technical specification, product registration, supplier eligibility, price, award or customer route for a particular offer.

WHO’s Kyrgyzstan country material frames the 2024–2030 cooperation strategy around jointly identified health priorities; a country-cooperation strategy does not identify a facility need, buyer, procurement package, product registration, reimbursement route or permitted clinical use.

The Ministry of Health and Social Protection is the accountable public-sector reference, while WHO/European Observatory material describes a largely public and centrally governed system with a small private sector. This does not identify a purchasing authority, facility need or commercial route for a named offer.

Turkmenistan approved a 2026–2052 scientific-medical diplomacy strategy and a 2026–30 action plan. An approved strategy is a high-level policy instrument; it does not establish a procurement package, budget, product need, registration outcome, hospital access, clinical acceptance, purchaser authority or payment route for a defined supplier.

Cabinet of Ministers Resolution No. 670 of 6 October 2026 approved national lists of vital medicines and medical devices for 2026 to 2028. The lists are a current public reference for product and health-system research, but inclusion or exclusion does not establish registration, procurement, reimbursement, hospital demand, import permission, supplier eligibility or sale of a particular product.

Original sources